Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018” research report to their offering. See more at- http://mrr.cm/ZXd

1. Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com

2. Introduction to Report
 Launch Date: August 20, 2014
 Number of Pages: 252
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 5,995
Price For Site User License: USD 11,990
Price For Global User License: USD 17,985
Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com

3. About the Report
The main drivers of growth in graft versus host disease
over the 2013-2018 forecast period include the increasing
numbers of allogeneic hematopoietic stem cell
transplants and the increasing use of biologic off-label
and marketed therapies in the 6MM.
Sanofi is a key player in the GVHD market with
Thymoglobuline and Lemtrada by infiltrating prophylaxis,
aGVHD and cGVHD. Gaining more and more ground in the
treatment management of cGVHD is Roche’s Rituxan that
Publisher estimates will be one of the bestselling biologics
in GVHD in the US by 2018.
www.MarketResearchReports.com

4. Research Finding
The graft-versus-host disease (GVHD) treatment market
value will increase from $297 million in 2013 to $407
million by 2018, at a Compound Annual Growth Rate
(CAGR) of 6.59%, according to research.
"OpportunityAnalyzer: Graft-Versus-Host Disease -
Opportunity Analysis and Forecasts to 2018" report states
that this growth, which will occur over six major markets
(6MM: the US, France, Germany, Italy, Spain and the UK),
will be strongest in the five European countries (5EU),
where multiple product launches will accelerate the
market value at a CAGR of 9.26% during the forecast
period.
Several products are due to enter the GVHD market by
2018, with Osiris Therapeutics and Mesoblast’s first-to-market
Prochymal expected to generate sales of $12.2
million in 2018.
www.MarketResearchReports.com

5. Key Findings
High uptake of off-label biologics (Rituxan, Lemtrada,
Remicade and Thymoglobuline)
No national guidelines are in place
GVHD remains a field of highly unattained unmet need
No consensus over clinical trial endpoints
Regulatory T cells (Tregs) are the focus of the early stage
pipeline
Huge opportunity exists in the chronic patient segment
of GVHD
Institutionally funded studies are the core of GVHD
treatment management
www.MarketResearchReports.com

6. Report Coverage
1. Introduction
2. Disease Overview
3. Epidemiology
4. Current Treatment Options
5. Unmet Need and Opportunity
6. Research and Development Strategies
7. Pipeline Assessment
8. Pipeline and Off-Label Valuation Analysis
9. Appendix
www.MarketResearchReports.com

7. Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
www.MarketResearchReports.com

8. How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/ZXd
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)
www.MarketResearchReports.com